Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with Karyopharm Therapeutics (NASDAQ: KPTI) to evaluate the combination of BMS’s cereblon E3 ligase modulator (CELMoD) candidate, mezigdomide, with Karyopharm’s first-in-class Exportin 1 (XPO1) inhibitor, Xpovio (selinexor), plus dexamethasone. This combination is targeted at relapsed/refractory multiple myeloma (r/rMM) patients who have not responded to T-cell engaging therapy or require an alternative to T-cell therapies.
Clinical Development Plan
According to Karyopharm CEO Richard Paulson, the oral combination therapy has demonstrated success in pre-clinical studies. The therapy is scheduled to enter clinical trials during the first half of 2024, with the objective response rate (ORR) and the clinical benefit rate (CBR) as primary endpoints. This strategic collaboration aims to explore new treatment options for patients with r/rMM, potentially offering a more effective and tolerable therapy.
Significance of the Collaboration
This partnership between BMS and Karyopharm underscores a commitment to innovation in oncology treatment and highlights the potential of combining different mechanisms of action to improve outcomes in patients with r/rMM. The upcoming clinical trials will provide crucial data on the efficacy and safety of this novel combination therapy.-Fineline Info & Tech
